SCHEMBL1232001

SCHEMBL1232001

O=C(O)c1c(O)cc[nH]c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
NAPRT Q6XQN6 1/20 0.45
DAO P14920 1/20 0.45
PARP1 P09874 5/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
RAB9A P51151 1/20 0.42
BLM P54132 1/20 0.42
PARP15 Q460N3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17597734 0.98 CA12 (0.46) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL17595029 0.98 CA12 (0.46) CA12CA1CA2CA7CA9
Terephthalamide SCHEMBL15399897 0.88 TYK2 (0.42) CA12CA1CA2CA7CA9
SCHEMBL2826027 0.81 DAO (0.43) CA12CA1CA2CA7CA9
SCHEMBL1643442 0.79 DAO (0.42) CA12CA1CA2CA7CA9
SCHEMBL26619127 0.78 NAPRT (0.55) NAPRTDAOPARP1KDM4EALDH1A1
SCHEMBL17029566 0.78 DAO (0.41) CA12CA1CA9NAPRTDAO
SCHEMBL2223763 0.77 NOTUM (0.45) NAPRTDAOPARP1KDM4EALDH1A1
SCHEMBL3653849 0.77 DPP4 (0.47) NAPRTKDM4EALDH1A1HSD17B10TDP1
SCHEMBL3648576 0.77 NAPRT (0.44) NAPRTDAOPARP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12002595-B2 Separation of metal ions by liquid-liquid extraction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-04 US claimed
EP-3107580-B1 USE OF A REVERSE-MICELLAR SYSTEM FOR DELIVERING CHELATORS OF RADIONUCLIDES AND METALS MEDESIS PHARMA (FR) 2024-02-14 EP claimed
US-20240000832-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE MEDESIS PHARMA (FR) 2024-01-04 US claimed
EP-4290532-A2 SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION The Regents of the University of California (US) 2023-12-13 EP claimed
EP-3520117-B1 SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION UNIV CALIFORNIA (US) 2023-11-08 EP claimed
US-20210315931-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE MEDESIS PHARMA (FR) 2021-10-14 US claimed
EP-3817725-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE Medesis Pharma (FR) 2021-05-12 EP claimed
EP-3615077-A1 ACUTE AND CHRONIC MITOCHONDRIAL ELECTRON TRANSPORT CHAIN DYSFUNCTION TREATMENTS AND GRAPHENIC MATERIALS FOR USE THEREOF William Marsh Rice University (US) 2020-03-04 EP claimed
WO-2020008032-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE MEDESIS PHARMA (FR) 2020-01-09 WO claimed
US-20190287691-A1 SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-09-19 US claimed
US-20140271825-A1 PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM ZONEONE PHARMA, INC. 2014-09-18 US claimed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP claimed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO claimed
US-20100317117-A1 SELECTIVE MEMBRANE EXTRACTION OF RADIOACTIVE ANALYTES LOS ALAMOS NATIONAL SECURITY, LLC (US) 2010-12-16 US claimed
EP-1423399-A4 HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS UNIV CALIFORNIA (US) 2008-05-07 EP claimed
US-6846915-B2 Hydroxypyridonate and hydroxypyrimidinone chelating agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-01-25 US claimed
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-01-13 US claimed
EP-1423399-A2 HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-06-02 EP claimed
US-20030095922-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-05-22 US claimed
WO-2003016923-A2 HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-02-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190287691-A1 SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION SLC39A14, SLC39A11, SLC39A7 CA12 351/4885CA1 243/4885CA2 18/4885
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents HAMP, GDI1, MPI CA12 920/4885CA1 416/4885CA2 272/4885
US-20210315931-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE MRE11, TSG101, CTSA CA12 1615/4885CA1 2491/4885CA2 3701/4885
US-12002595-B2 Separation of metal ions by liquid-liquid extraction SLC39A14, SLC39A11, SLC39A7 CA12 351/4885CA1 243/4885CA2 18/4885
US-20240000832-A1 TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE MRE11, TSG101, CTSA CA12 1615/4885CA1 2491/4885CA2 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.